Tina Banerjee

Equity research enthusiast, with interest in global healthcare. Smartkarma Insight Provider.

[Tina Banerjee @Generic_Tina]

Chugai Pharma (4519 JP) reports growth in both domestic and overseas markets in 1H26. 2026 guidance reiterated. Hemlibra export still key but new products gaining momentum. https://t.co/UqPBHFQmzs

[Tina Banerjee @Generic_Tina]

Manipal Health will launch its India IPO on July 29. The IPO price band is set at INR560 to INR590 per share. The IPO subscription will close on July 31, with expected listing on August 5. https://t.co/nK64dCIWpO

[Tina Banerjee @Generic_Tina]

Hengrui’s camrelizumab got indication expansion approval for cervical cancer. BeOne announced $300M expansion plan for US facility. Samsung Biologics is acquiring PolyPeptide for CHF1.46B. https://t.co/UbokmFlmgm

[Tina Banerjee @Generic_Tina]

Samsung Biologics reports 30% revenue growth for 2Q26 and is on track to meet the upper end of FY guidance range. The company is acquiring PolyPeptide, a top-tier global peptide CDMO, for $1.8B. https://t.co/QNTI1AMB2e

[Tina Banerjee @Generic_Tina]

INDO-MIM Ltd launches India IPO to raise INR 38.1B for repayment of borrowings and working capital, showcasing leadership position, diverse product portfolio and technological expertise. https://t.co/eiBaz9rYWw

[Tina Banerjee @Generic_Tina]

Zhongji Innolight launch HK IPO to raise HK$55B for R&D, global expansion, acquisitions, and working capital, with justified valuation reflecting market leadership in optical interconnect solutions. https://t.co/yuKIk9KuGu

[Tina Banerjee @Generic_Tina]

Bumrungrad Hospital shares advanced 27%, while its larger peer Bangkok Dusit Medical Services shares fell 8% over the last one year. Financial performance justifies share price movements. https://t.co/xUsnyLkf6A

[Tina Banerjee @Generic_Tina]

Ascentage Pharma plans to raise up to US$200M through ADS offering. Olverembatinib, Lisaftoclax gradually gaining momentum. 2027 likely to be an inflection point with market and indication expansion. https://t.co/ggXX7tWqzW

[Tina Banerjee @Generic_Tina]

Mani Inc sees revenue growth and margin improvement in 9MFY26. FY26 guidance revised upward for strong financial performance. Ongoing dental segment recovery in China augur well for long term. https://t.co/QZK4cZLuMi

[Tina Banerjee @Generic_Tina]

Kelun Biotech’s sac-TMT met primary endpoint in Phase 3 trial. FDA approves Eisai’s Leqembi Iqlik for Alzheimer’s starting therapy. Mesoblast met target of 300 patients treated in Phase 3 trial. https://t.co/cfwCXGGnLz

[Tina Banerjee @Generic_Tina]

Mesoblast treated 300 patients in Phase 3 trial of rexlemestrocel-L for chronic low back pain. Ryoncil annual revenue exceeded $100M. Mesoblast shares gained 33% over the last five sessions. https://t.co/trUkSyslo5

[Tina Banerjee @Generic_Tina]

Genfleet Therapeutics (2595 HK) announces placement of 13.6M shares at HK$34.69/share, aiming to advance core products, enhance R&D, and expand portfolio. Rightly placed at this point to accelerate. https://t.co/629YpQwIE0

[Tina Banerjee @Generic_Tina]

Eisai got FDA approval for once-weekly Leqembi SC as an initiation dose for early Alzheimer’s disease. Leqembi SC already got FDA approval for maintenance dosing after initial treatment. https://t.co/ajzhmY2L09

[Tina Banerjee @Generic_Tina]

CSPC Pharmaceutical partners with AstraZeneca to develop siRNA candidates for renal diseases. Licensing revenue will help compensate for revenue drop for now. Approvals and new launches remain key. https://t.co/fiL4lldwP7

[Tina Banerjee @Generic_Tina]

Shanghai Henlius Biotech is pursuing globalization for serplulimab. With continuous indication and geography expansion, serplulimab has potential to fetch annual revenue of ~$1.5B by 2030. https://t.co/t0js55fVkW

[Tina Banerjee @Generic_Tina]

Sino Bio stuck outlicensing deal with AstraZeneca. Hansoh’s ADC drug candidate met primary endpoint in Phase 3 trial. China will review Astellas’ NDA for Padcev for muscle-invasive bladder cancer. https://t.co/iCcuphc8vH

[Tina Banerjee @Generic_Tina]

Sichuan Kelun Biotech announced the placement of 5.8M shares for subscription at HK$470.2 per share. The placing price represents a discount of 8.5% to the undisturbed price. https://t.co/ZSKLNKztoG

[Tina Banerjee @Generic_Tina]

Q&M Dental aims to pursue regional growth strategy with focus on M&A alongside organic growth, across Australia, Thailand, Singapore, and China to deliver sustainable growth. https://t.co/NzCAYVR0HX

[Tina Banerjee @Generic_Tina]

Takeda Pharmaceutical reports positive Phase 3 results for zasocitinib and oveporexton, showcasing potential for sustained growth and pipeline strength. https://t.co/nXWFsDbmPb

[Tina Banerjee @Generic_Tina]

Celltrion reported record-breaking Q2 result, driven by high-margin new products and structurally improved cost base. 2H sales will outpace 1H, due to seasonal factors and major tender opportunities. https://t.co/YrTIeOewaO